Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?

Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	$251M+3,686%	$209M+2,886%	$128M+381%	$108M+209%	-$7M+79.1%
Depreciation and amortization	$9M-35.7%	$10M-37.5%	$13M-11.9%	$14M-3.4%	$14M-13.8%
Stock-based compensation	$29M+20.8%	$26M+8.3%	$27M+16.1%	$26M+15.6%	$24M+10.3%
Deferred income taxes	-$17M-950%	-$46M-757%	$29M+163%	$38M+168%	$2M+104%
Impairment charges	$25M—	$19M—	——	——	——
Change in accounts receivable	$28M+567%	-$3M-400%	$7M+33.3%	-$20M-189%	-$6M-129%
Change in inventories	——	——	——	-$14M-137%	$11M-65.1%
Change in other assets	-$49M—	-$49M—	——	——	——
Change in other liabilities	——	——	——	——	——
Other working capital changes	——	——	——	——	——
Non-cash operating lease expense	$10M—	$10M—	$11M—	$13M—	——
Loss on extinguishment of debt	——	——	——	——	——
Net cash from operating activities	-$111M—	-$27M—	——	——	——
Capital expenditures	$81M+153%	$66M+128%	$58M+287%	$45M+350%	$32M+300%
Acquisitions, net of cash acquired	——	$0—	$0-100%	$0-100%	$0-100%
Proceeds from maturities/sales of investments	$19M-79.3%	$19M-83.8%	$43M-64.2%	$86M-19.2%	$92M-28.0%
Other investing activities	——	$0—	$0+100%	$0+100%	$0+100%
Purchases of fixed maturity securities	$20M+11.1%	$20M+17.6%	$17M-32.7%	$19M-39.7%	$18M-52.3%
Net cash from investing activities	-$80M-305%	-$66M-196%	-$34M-191%	$21M+198%	$39M+184%
Repurchases of common stock	——	——	——	——	$148M+144%
Proceeds from issuance of debt	——	——	——	——	$249M+200%
Repayments of debt	$346M+42.4%	$17M-92.9%	$250M+4,900%	$247M+3,429%	$243M+2,330%
Proceeds from issuance of common stock	——	——	——	——	——
Taxes paid for net share settlement	——	——	——	——	——
Other financing activities	——	——	——	——	——
Payment of debt issuance costs	——	——	——	——	$1.5M+200%
Net cash from financing activities	-$6M—	-$30M—	——	——	——
Effect of exchange rate changes on cash	-$1M—	-$1M—	$0—	$1M—	——
Net increase (decrease) in cash	-$197M-259%	-$124M-4,233%	$159M+211%	$206M+185%	$124M+130%
Asset write-downs	$25M—	$19M—	——	——	——
Foreign currency remeasurement (loss) gain on debt	-$2M-200%	-$1M-150%	$7M+1,500%	$7M+40.0%	$2M-76.5%
Accrued legal and settlement expenses	——	——	——	——	——
Increase (Decrease) in Other Operating Assets	-$49M—	-$49M—	——	——	——
Operating lease right-of-use asset amortization	$10M—	$10M—	$11M—	$13M—	——
Other Noncash Income (Expense)	——	——	——	——	——
Payment for (Proceeds from) Other Investing Activity	——	$0—	$0+100%	$0+100%	$0+100%
Payments to Acquire Held-to-Maturity Securities	$20M+11.1%	$20M+17.6%	$17M-32.7%	$19M-39.7%	$18M-52.3%
Proceeds from disposal of certain strategic investments	——	$1M—	$750K—	$500K—	$250K—
Payments Of Debt Issuance Costs	——	——	——	——	$1.5M+200%
Other, net	——	——	——	——	——
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	-$1M—	-$1M—	$0—	$1M—	——
Free cash flow	-$192M—	-$93M—	——	——	——
Free cash flow	-$192M—	-$93M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Indivior Pharmaceuticals, Inc. 's cash flow data come from?: Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.